ASH 2016 | Using next-generation sequencing to identify biomarkers in CML
Most patients with chronic myeloid leukemia (CML) do well with tyrosine kinase inhibitors (TKIs), but there are a minority who show resistance to imatinib, which is about to become a biosimilar in the UK. It will be important to find biomarkers that identify these patients at diagnosis so they can potentially start on a second-generation TKI in the first-line. Georgios Nteliopoulos, MSc, PhD from Imperial College London, London UK discusses the aims of his latest trial, which was presented at the 2016 American Society of Hematology (ASH) Annual Meeting, held in San Diego, CA. Dr Nteliopoulos talks to us about the issues regarding poor response and resistance in the treatment of CML. The aim of the study is to perform next-generation sequencing (NGS) on newly diagnosed chronic-phase CML patients in order to identify factors that will predict how they will respond to treatment. New biomarkers, like these, will help to better diagnose and treat patients. This video has been supported by Incyte through an unrestricted educational grant.
Get great new content delivered to your inboxSign up